News Search Results
Dec 10, 2025, 18:31 ET Bluerock Announces Listing of Bluerock Total Income+ Real Estate Fund Shares and New Fund Name
with possible disruption to the Fund's operations or the economy generally due to hostilities, terrorism, natural disasters or pandemics such as COVID-19, future changes in laws or regulations and conditions in the Fund's operating area, unexpected costs, the ability of the Fund to complete the listing
More news about: Bluerock
Dec 10, 2025, 15:19 ET Two Steps Forward: Sofaida's Story
father carried her to a learning centre each day. But when she reached adolescence, her family stopped taking her due to cultural beliefs, and then COVID-19 paused activities completely. Sofaida was out of the classroom for years.Fortunately, in 2022, she enrolled in Save the Children's Community-Based
More news about: Education Cannot Wait
Dec 10, 2025, 07:00 ET NaaS Technology Inc. Regains Compliance with Nasdaq Minimum Market Value of Listed Securities Requirement
NaaS' ability to protect and enforce its intellectual property rights; NaaS' ability to attract and retain qualified executives and personnel; the COVID-19 pandemic and the effects of government and other measures that have been or will be taken in connection therewith; U.S.-China trade war and its effect
More news about: NaaS Technology Inc.
Dec 10, 2025, 07:00 ET CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025
FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb is not yet approved or cleared in the United States.In the U.S. and Canada, CytoSorbents is
More news about: Cytosorbents Corp
Dec 09, 2025, 18:22 ET Energy Services of America Reports Fourth Quarter and Full Year Fiscal 2025 Results
Such factors include, among others, general economic and business conditions, changes in business strategy or development plans, the effect of the COVID-19 pandemic, the integration of acquired business and other factors referenced in this release, risks and uncertainties related to the restatement of
More news about: Energy Services of America Corporation
Dec 09, 2025, 14:05 ET Willig, Williams & Davidson Expands Labor Law Practice with Three New Associates
they earn and deserve, and I look forward to guiding our clients with my knowledge and insight."Inspired by labor demonstrations during the COVID-19 pandemic that united people from various backgrounds, Nguyen is a passionate advocate for working people and unions. She earned her law degree specifically
More news about: Willig, Williams & Davidson
Dec 09, 2025, 13:21 ET Industry Veteran Ron Buford to Retire from CORE X PREMIER After 46-Year Cold Storage Career
Global Cold Chain Alliance (GCCA), the industry's leading trade association, including a historic tenure as the longest-serving chairman during the COVID-19 pandemic."My journey has given me the opportunity to meet and touch so many great people at each of the stops I made over these years," Buford
More news about: CORE X Partners
Dec 09, 2025, 10:20 ET Immunostimulant Market to Reach $288.82 billion, Globally, by 2034 at 9.9% CAGR: Allied Market Research
rising incidence of infectious diseases, increasing prevalence of cancer and autoimmune disorders, and heightened focus on immune health following the COVID-19 pandemic. According to the World Health Organization, infectious diseases remain one of the leading causes of morbidity and mortality worldwide, underscoring
More news about: Allied Market Research
Dec 09, 2025, 09:00 ET GENOMMA LAB INTERNACIONAL ANNOUNCES FOURTEENTH DIVIDEND PAYMENT
forward-looking statements, which speak only as of their dates. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays,
More news about: Genomma Lab Internacional, S.A.B. de C.V.
Dec 09, 2025, 08:01 ET Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond
More news about: Lucid Diagnostics
Dec 09, 2025, 08:01 ET WellNow Urgent Care Partners with Utica University to Expand Healthcare for Students
partnership addresses college students' unique healthcare needs by providing expert evaluation and treatment for common conditions including colds and flu, COVID-19, testing and treatment for STIs and UTIs, rashes and allergies, lab testing, medication refills, and pink eye. Students benefit from board-certified
More news about: WellNow Urgent Care
Dec 09, 2025, 07:30 ET Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
pneumonia (14%), COVID-19 (4.7%), musculoskeletal pain (3.9%), hemorrhage (2.3%), pleural effusion (2.3%), and sepsis (2.3%) occurring in ≥2% of patients. Fatal ARs within 28 days of last dose occurred in 7% of patients, most commonly due to infections (4.7%), including COVID-19 (3.1% of all patients).Dose
More news about: Eli Lilly and Company
Dec 09, 2025, 05:57 ET American Lung Association Launches Campaign to Help New England Residents Stay Healthy This Winter
that protect against flu, COVID-19 and RSVCHICAGO, Dec. 9, 2025 /PRNewswire/ -- Each winter, too many families across New England are impacted by respiratory diseases like the flu, COVID-19 and respiratory syncytial
More news about: American Lung Association
Dec 09, 2025, 04:44 ET Seven Zonta Clubs in Hong Kong unite to promote "Zonta Says NO to Violence Against Women" campaign and to support the Po Leung Kuk's mobile art exhibition "Violence? Love!!: A Voyage of Discovery"
cultural barriers; it occurs at home, in the workplace, and in public spaces, impacting millions of women and girls in both peacetime and conflict. The COVID-19 pandemic intensified violence against women, with a 2022 study revealing that nearly 40% of women in Hong Kong have experienced sexual abuse. The
More news about: Zonta Clubs in HK
Dec 08, 2025, 09:15 ET AMBITIONS ENTERPRISE MANAGEMENT CO. L.L.C Reports Unaudited Financial Results for the Six Months Ended June 30, 2025
June 30, 2024, primarily due to the increased demand for MICE services from the corporate customers driven by the recovery in MICE travel from the COVID-19 pandemic and the UAE government's support for the tourism industry.Cost of revenues increased by 17% to approximately US$7.9 million
More news about: AMBITIONS ENTERPRISE MANAGEMENT CO. L.L.C
Dec 08, 2025, 09:03 ET New Symptom-Management Guide Offers Practical Support for People Undergoing Metastatic Breast Cancer Treatment
people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era
More news about: Viver Health
Dec 08, 2025, 08:00 ET Israir Group Concludes the Best Quarter in Its History with a Net Profit of Approximately USD 35 Million, a 75% Increase, and EBITDAR of USD 46 Million
compared to 12 in the same quarter last yearNext month, the company will repay convertible bonds issued to the Ministry of Finance during the COVID-19 (Omicron) period, totaling approx. USD 9.5 millionHighlights for the first nine months of 2025:Revenues –
More news about: Israir Group
Dec 07, 2025, 16:30 ET Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
pneumonia (14%), COVID-19 (4.7%), musculoskeletal pain (3.9%), hemorrhage (2.3%), pleural effusion (2.3%), and sepsis (2.3%) occurring in ≥2% of patients. Fatal ARs within 28 days of last dose occurred in 7% of patients, most commonly due to infections (4.7%), including COVID-19 (3.1% of all patients).Dose
More news about: Eli Lilly and Company
Dec 06, 2025, 15:40 ET Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC
patients with NRG1 gene fusion positive pancreatic adenocarcinoma who received BIZENGRI.There were 2 fatal adverse reactions, one due to COVID-19 and one due to respiratory failure. In patients with NRG1 gene fusion positive pancreatic adenocarcinoma who received BIZENGRI the most common
More news about: Partner Therapeutics, Inc.
Dec 06, 2025, 09:30 ET Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
infections in 1% of patients. Overall, 5% (13/285) of patients had Grade 5 infections, 2.5% of which were due to COVID-19. Patients treated with CARVYKTI® had an increased rate of fatal COVID-19 infections compared to the standard therapy arm.Monitor patients for signs and symptoms of infection
More news about: Johnson & Johnson
Dec 05, 2025, 11:19 ET Seegene gründet Tochtergesellschaft in Frankreich und baut Präsenz in Europa weiter aus
Vertrieb im Zusammenhang mit syndromischen Echtzeit-PCR-Technologien. Dieses Fachwissen wurde, während der COVID-19-Pandemie besonders deutlich, als Seegene mehr als 340 Millionen COVID-19-Tests an mehr als 100 Länder weltweit lieferte. Das Hauptmerkmal der syndromischen Echtzeit-PCR-Technologie
More news about: Seegene Inc.
Dec 05, 2025, 11:17 ET Seegene Establishes French Subsidiary to Expand European Footprint
and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability
More news about: Seegene Inc.
Dec 05, 2025, 10:55 ET Seegene Establishes French Subsidiary to Expand European Footprint
and business related to syndromic real-time PCR technologies. This expertise was particularly highlighted during the COVID-19 pandemic when Seegene provided over 340 million COVID-19 tests to more than 100 countries worldwide. The core feature of Seegene's syndromic real-time PCR technology is the ability
More news about: Seegene Inc.
Dec 05, 2025, 10:00 ET Seegene establece filial en Francia para ampliar su presencia en Europa
con tecnologías sindrómicas de PCR en tiempo real. Esta experiencia destacó especialmente durante la pandemia de COVID-19, cuando Seegene suministró más de 340 millones de pruebas de COVID-19 a más de 100 países en todo el mundo.La característica central de la tecnología sindrómica de PCR en tiempo
More news about: Seegene Inc.
Dec 05, 2025, 08:45 ET PAVS Achieves 18,037% YoY Revenue Increase in 2025 Interim Results
technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic, the COVID-19 outbreak and its impact on our operations and assumptions underlying or related to any of the foregoing and other risks contained in reports filed
More news about: Paranovus Entertainment Technology Ltd